Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a high affinity for the GLP-1 receptor, used in the treatment of type 2 diabetes and, more recently, for weight management in individuals with or without diabetes It is a synthetic analog of the naturally occurring hormone GLP-1, which is involved in appetite regulation and insulin secretion.


Mechanism of Action

Semaglutide works by mimicking the action of the endogenous hormone GLP-1, thereby enhancing the release of insulin in response to elevated blood glucose levels. This process improves glycemic control and reduces the risk of hyperglycemia in individuals with type 2 diabetes. Additionally, Semaglutide slows gastric emptying, which prolongs the sensation of fullness after eating and reduces appetite, leading to a decrease in caloric intake and weight loss. Its action on the GLP-1 receptors in the brain also contributes to appetite suppression.


Benefits and Uses

Glycemic Control in Type 2 Diabetes: Improves blood sugar levels by enhancing insulin secretion and reducing glucagon release.

Weight Loss: Significantly reduces body weight through decreased appetite and caloric intake, making it beneficial for obese and overweight patients, including those with type 2 diabetes.

Cardiovascular Health: Semaglutide has shown potential in reducing the risk of major adverse cardiovascular events in individuals with type 2 diabetes.

The combination of glycemic control, weight management, and potential cardiovascular benefits makes Semaglutide a valuable therapeutic option for a broad spectrum of patients.

This content has been restricted to logged in users only. Please login to view this content.